BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that it has successfully ...

BILLERICA, Mass.--(BUSINESS WIRE)-- Quanterix Corporation (QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that the HD-X Simoa Immunoassay ...

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that David R. Walt, ...

Ultra-sensitive Simoa® HD-X technology powers new findings that detect rapid reduction of plasma P-tau217 from donanemab, Lilly’s investigational antibody therapy for Alzheimer's disease at 12 weeks ...

Publication in the journal ‘Brain’ confirms complementary roles of the biomarkers for predicting relapse and chronic disability progression in multiple sclerosis (MS) Simoa technology paired with an ...

BILLERICA, Mass.--(BUSINESS WIRE)-- Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that David R. Walt, ...

The ability to detect neurological biomarkers in blood is opening new windows on the brain. It all starts with sensitivity. 24 October 2024 The field of blood-based biomarkers is abuzz with ...

Quanterix is developing and manufacturing a fully-automated instrument and low cost consumables for use in both the life sciences and in vitro diagnostics (IVD) markets. SiMoA, which has been ...

Powering Precision Health 2022 Alzheimer’s podcast announced in recognition of Biomarker Factory launch “Researchers are exploring the utility of ultrasensitive plasma biomarkers for drug trial ...